Literature DB >> 24000072

N-Acetyl cysteine reverses social isolation rearing induced changes in cortico-striatal monoamines in rats.

Marisa Möller1, Jan L Du Preez, Francois P Viljoen, Michael Berk, Brian H Harvey.   

Abstract

Schizophrenia is causally associated with early-life environmental stress, implicating oxidative stress in its pathophysiology. N-acetyl cysteine (NAC), a glutathione precursor and antioxidant, is emerging as a useful agent in the adjunctive treatment of schizophrenia and other psychiatric illnesses. However, its actions on brain monoamine metabolism are unknown. Social isolation rearing (SIR) in rats presents with face, predictive and construct validity for schizophrenia. This study evaluated the dose-dependent effects of NAC (50, 150 and 250 mg/kg/day × 14 days) on SIR- vs. socially reared induced changes in cortico-striatal levels of dopamine (DA), serotonin (5-HT) noradrenaline (NA) and their associated metabolites. SIR induced significant deficits in frontal cortical DA and its metabolites, 3,4-dihydroxyphenylacetic acid (Dopac) and homovanillic acid (HVA), reduced 5-HT and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA), and reduced levels of the NA metabolite, 3-methoxy-4-hydroxyphenylglycol (MHPG). In addition, significant elevations in frontal cortical NA and striatal DA, Dopac, HVA, 5-HT, 5-HIAA, NA and MHPG were also observed in SIR rats. NAC at 150 and 250 mg/kg reversed all cortico-striatal DA, Dopac, HVA, 5-HT, 5-HIAA and striatal NA alterations in SIR animals, with 250 mg/kg of NAC also reversing alterations in cortico-striatal MHPG. In conclusion, SIR profoundly alters cortico-striatal DA, 5-HT and NA pathways that parallel observations in schizophrenia, while these changes are dose-dependently reversed or abrogated by sub-chronic NAC treatment. A modulatory action on cortico-striatal monoamines may explain NACs' therapeutic use in schizophrenia and possibly other psychiatric disorders, where redox dysfunction or oxidative stress is a causal factor.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24000072     DOI: 10.1007/s11011-013-9433-z

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  76 in total

Review 1.  Glutathione metabolism and its implications for health.

Authors:  Guoyao Wu; Yun-Zhong Fang; Sheng Yang; Joanne R Lupton; Nancy D Turner
Journal:  J Nutr       Date:  2004-03       Impact factor: 4.798

2.  Changes in basal and stimulated release of endogenous serotonin from different nuclei of rats subjected to two models of depression.

Authors:  E H Jaffe; V De Frias; C Ibarra
Journal:  Neurosci Lett       Date:  1993-11-12       Impact factor: 3.046

3.  The NADPH oxidase NOX2 controls glutamate release: a novel mechanism involved in psychosis-like ketamine responses.

Authors:  Silvia Sorce; Stefania Schiavone; Paolo Tucci; Marilena Colaianna; Vincent Jaquet; Vincenzo Cuomo; Michel Dubois-Dauphin; Luigia Trabace; Karl-Heinz Krause
Journal:  J Neurosci       Date:  2010-08-25       Impact factor: 6.167

4.  The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial.

Authors:  Michael Berk; Olivia Dean; Sue M Cotton; Clarissa S Gama; Flavio Kapczinski; Brisa S Fernandes; Kristy Kohlmann; Susan Jeavons; Karen Hewitt; Christine Allwang; Heidi Cobb; Ashley I Bush; Ian Schapkaitz; Seetal Dodd; Gin S Malhi
Journal:  J Affect Disord       Date:  2011-06-29       Impact factor: 4.839

Review 5.  Nitric oxide and schizophrenia: present knowledge and emerging concepts of therapy.

Authors:  Hans-Gert Bernstein; Gerburg Keilhoff; Johann Steiner; Henrik Dobrowolny; Bernhard Bogerts
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-11       Impact factor: 4.388

Review 6.  Prenatal exposure to infection: a primary mechanism for abnormal dopaminergic development in schizophrenia.

Authors:  Urs Meyer; Joram Feldon
Journal:  Psychopharmacology (Berl)       Date:  2009-03-11       Impact factor: 4.530

7.  Cortical/hippocampal monoamines, HPA-axis changes and aversive behavior following stress and restress in an animal model of post-traumatic stress disorder.

Authors:  Brian H Harvey; Linda Brand; Zakkiyya Jeeva; Dan J Stein
Journal:  Physiol Behav       Date:  2006-03-06

Review 8.  The possible involvement of metabotropic glutamate receptors in schizophrenia.

Authors:  Amir Krivoy; Tsvi Fischel; Abraham Weizman
Journal:  Eur Neuropsychopharmacol       Date:  2007-12-11       Impact factor: 4.600

Review 9.  Proposal for a noradrenaline hypothesis of schizophrenia.

Authors:  Kenichi Yamamoto; Oleh Hornykiewicz
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2004-08       Impact factor: 5.067

10.  Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics.

Authors:  J N Joyce; A Shane; N Lexow; A Winokur; M F Casanova; J E Kleinman
Journal:  Neuropsychopharmacology       Date:  1993-06       Impact factor: 7.853

View more
  13 in total

1.  Ozone exposure of Flinders Sensitive Line rats is a rodent translational model of neurobiological oxidative stress with relevance for depression and antidepressant response.

Authors:  Mmalebuso L Mokoena; Brian H Harvey; Francois Viljoen; Susanna M Ellis; Christiaan B Brink
Journal:  Psychopharmacology (Berl)       Date:  2015-04-17       Impact factor: 4.530

Review 2.  Targeting Oxidative Stress and Aberrant Critical Period Plasticity in the Developmental Trajectory to Schizophrenia.

Authors:  Kim Q Do; Michel Cuenod; Takao K Hensch
Journal:  Schizophr Bull       Date:  2015-06-01       Impact factor: 9.306

3.  Social isolation alters central nervous system monoamine content in prairie voles following acute restraint.

Authors:  Neal McNeal; Eden M Anderson; Deirdre Moenk; Diane Trahanas; Leslie Matuszewich; Angela J Grippo
Journal:  Soc Neurosci       Date:  2017-01-09       Impact factor: 2.083

4.  N-acetyl cysteine reverses bio-behavioural changes induced by prenatal inflammation, adolescent methamphetamine exposure and combined challenges.

Authors:  Twanette Swanepoel; Marisa Möller; Brian Herbert Harvey
Journal:  Psychopharmacology (Berl)       Date:  2017-11-08       Impact factor: 4.530

Review 5.  A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates.

Authors:  Sarel J Brand; Marisa Moller; Brian H Harvey
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

Review 6.  Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A "central hub" in schizophrenia pathophysiology?

Authors:  P Steullet; J H Cabungcal; A Monin; D Dwir; P O'Donnell; M Cuenod; K Q Do
Journal:  Schizophr Res       Date:  2014-07-05       Impact factor: 4.939

Review 7.  Methylene blue and its analogues as antidepressant compounds.

Authors:  Anzelle Delport; Brian H Harvey; Anél Petzer; Jacobus P Petzer
Journal:  Metab Brain Dis       Date:  2017-07-31       Impact factor: 3.584

8.  Social isolation rearing-induced anxiety and response to agomelatine in male and female rats: Role of corticosterone, oxytocin, and vasopressin.

Authors:  Brian H Harvey; Wilmie Regenass; Walter Dreyer; Marisa Möller
Journal:  J Psychopharmacol       Date:  2019-02-21       Impact factor: 4.153

Review 9.  The neuropsychiatric manifestations of COVID-19: Interactions with psychiatric illness and pharmacological treatment.

Authors:  Esmé Jansen van Vuren; Stephan F Steyn; Christiaan B Brink; Marisa Möller; Francois P Viljoen; Brian H Harvey
Journal:  Biomed Pharmacother       Date:  2021-01-01       Impact factor: 6.529

10.  Studies on Haloperidol and Adjunctive α-Mangostin or Raw Garcinia mangostana Linn Pericarp on Bio-Behavioral Markers in an Immune-Inflammatory Model of Schizophrenia in Male Rats.

Authors:  Jana Lotter; Marisa Möller; Olivia Dean; Michael Berk; Brian H Harvey
Journal:  Front Psychiatry       Date:  2020-03-31       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.